Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Introns × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 22 Genitourinary 8 Gastrointestinal 6 Other hematologic neoplasm 4 Plasma cell 3 Sarcoma 2 Lymphoid 2 Breast 2 NET 1 Gynecologic 1 Endocrine 1 CNS 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 33 Everolimus 29 Magnetic Resonance Spectroscopy 20 pembrolizumab 17 Temozolomide 16 Nivolumab 14 Cisplatin 14 lenvatinib 13 gallium Ga 68 dotatate 13 cabozantinib 13 3-Iodobenzylguanidine 13 lanreotide 12 Capecitabine 12 trametinib 11 dabrafenib 11 Surgical Procedures, Operative 10 Octreotide 10 Bevacizumab 10 Surveys and Questionnaires 9 Positron Emission Tomography Computed Tomography 9 Paclitaxel 9 Ipilimumab 8 Carboplatin 8 Blood Specimen Collection 8 177Lu-octreotide, DOTA(0)-Tyr(3)- 8 fluorodopa F 18 7 Sunitinib 7 Sorafenib 7 Somatostatin 7 Radiotherapy 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01860742 2016-04-05

CASTOR

Jules Bordet Institute

Phase 3 Withdrawn

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡